Entera Bio (ENTX) director buys 20,000 shares in open market

Rhea-AI Filing Summary

Entera Bio Ltd. director Germano Geno J reported an open-market purchase of 20,000 Ordinary Shares on March 9, 2026 at a price of 1.30 per share. After this transaction, he directly owns 40,000 Ordinary Shares, doubling his reported direct stake.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Germano Geno J

(Last) (First) (Middle)

KIRYAT HADASSAH, MINRAV BUILDING

5TH FLOOR

(Street)

JERUSALEM L3 9112002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	03/09/2026		P		20,000	A	$1.3	40,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Entera Bio (ENTX) director Germano Geno J report?

Director Germano Geno J reported buying 20,000 Entera Bio Ordinary Shares in an open-market transaction. The shares were purchased on March 9, 2026 at a price of 1.30 per share, increasing his direct ownership to 40,000 shares after the trade.

At what price did Entera Bio (ENTX) director purchase the shares?

The director bought Entera Bio Ordinary Shares at 1.30 per share in an open-market transaction. This price applied to all 20,000 shares acquired on March 9, 2026, as disclosed in the Form 4 insider trading report for Germano Geno J.

How many Entera Bio (ENTX) shares does the director hold after this Form 4 transaction?

Following the reported purchase, the director directly holds 40,000 Entera Bio Ordinary Shares. The Form 4 shows he acquired 20,000 shares on March 9, 2026, and lists 40,000 total shares owned directly after completing this open-market buy transaction.

Was the Entera Bio (ENTX) insider transaction a buy or a sell?

The insider transaction was a buy, specifically an open-market purchase of Ordinary Shares. The Form 4 classifies the trade with code “P” for purchase and identifies the transaction direction as a net buy of 20,000 shares on March 9, 2026.

Does the Entera Bio (ENTX) Form 4 show any derivative transactions for the director?

The Form 4 does not report any derivative transactions for the director. The derivative section is empty, and the filing only shows a single non-derivative open-market purchase of 20,000 Ordinary Shares, resulting in 40,000 Ordinary Shares held directly afterward.